Account
Watchlists
Bookmarks
Pricing
Bearish
5
Neutral
4
Bullish
5
Bearish
6
Neutral
4
Bullish
36
Bearish
1
Neutral
0
Bullish
31
Investor Presentation
Q3 FY25
Investor Presentation
Q3 FY25
Investor Presentation
Q2 FY25
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Home
Dashboard
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2025
Nectar Lifesciences Ltd is a leading global pharmaceutical company specializing in the manufacturing of Cephalosporin APIs and formulations. It holds a strong market position due to its integrated manufacturing ecosystem, allowing it to excel in advanced pharmaceutical production and distribution capabilities.
The company's recent performance highlights a significant increase in PAT by 399.36% YoY in Q3 FY25, driven by operational efficiencies and process improvements.
Nectar is actively expanding its contract development and manufacturing organization (CDMO) business, leveraging its extensive manufacturing capabilities to enhance customer relationships and reduce supply chain risks.
The company is strategically reducing long-term debt to zero by FY26 through efficient cost management, which is expected to enhance profitability and facilitate self-funded growth initiatives.
Pharmaceuticals
Pharmaceuticals - Indian - Bulk Drugs & Formln M/S
471 Cr
High Risk
—
30.8
—
0.7
44.90
13.25
Sales CAGR
1Y
-0.84%
3Y
-0.29%
5Y
-6.28%
10Y
0.69%
Profit CAGR
1Y
-2373.60%
3Y
—
5Y
—
10Y
—
ROE
TTM
-17.19%
3Y
-4.30%
5Y
-3.46%
10Y
0.57%
ROCE
TTM
-12.07%
3Y
1.57%
5Y
3.19%
10Y
8.61%
| Symbol | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
414.60 | 497 Cr | — | 3.08 | 0.00 | — | — | 0.00 | |
21.00 | 471 Cr | — | 0.66 | 0.00 | -17.19 | -12.07 | -19.92 | |
751.25 | 429 Cr | — | 1.09 | 0.66 | -3.83 | -3.33 | -2.83 | |
1397.30 | 422 Cr | 22.59 | 2.05 | 0.11 | 9.06 | 12.31 | 4.86 | |
50.70 | 418 Cr | 36.74 | 6.25 | 0.00 | 16.97 | 20.65 | 8.26 | |
106.10 | 406 Cr | 29.07 | 1.93 | 0.00 | 6.64 | 11.47 | 2.73 | |
305.00 | 377 Cr | 28.54 | 4.00 | 0.65 | 12.57 | 13.83 | 7.53 |
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Performance
UNDER PERFORMER
Valuation
UNDERVALUED
Growth
STABLE
Profitability
LOW MARGIN
Technicals
Bullish
Risk
HIGH RISK
Market Cap
₹ 471 Cr
P/E
—
Regulatory Filing
1 day ago
Acquisition Disclosure by Rajasthan Global Securities
Rajasthan Global Securities Pvt Ltd has disclosed under SEBI regulations its acquisition of additional shares in Nectar Lifesciences Limited, increasing its holding to 5.07%.
Buyback Offer
6 days ago
Buyback Shares Corrigendum Announcement
Nectar Lifesciences Ltd. issued a corrigendum related to their public announcement for a buyback of equity shares, detailing the publication of the corrigendum in various newspapers.
